- Ticker
- ACLX
- Price
- 32.13
- Stock movement down
- -0.57 (-1.74%)
- Company name
- Arcellx Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Markedsværdi
- 1.41B
- Ent værdi
- 1.45B
- Pris/omsætning
- -
- Pris/bog
- 5.96
- Udbytte afkast
- -
- Udbyttevækst
- -
- Vekst år
- -
- FCF-udbetaling
- -
- Efterfølgende P/E
- -
- Fremtidig P/E
- -
- PEG
- -
- EPS-vekst
- -
- 1 års afkast
- 114.20%
- 3 års afkast
- -
- 5 års afkast
- -
- 10 års afkast
- -
Senest opdateret: 2023-02-06
UDBYTTE
ACLX betaler ikke udbytte
VÆRDIANSÆTTELSE
Værdiansættelsesforhold
Loading...
Værdiansættelsesforhold-data
| Efterfølgende P/E | - |
| Pris til OCF | - |
| Pris til FCF | - |
| Pris til EBITDA | - |
| EV i forhold til EBITDA | - |
Værdiansættelse (salg/bogført værdi)
Loading...
Værdiansættelse (salg/bogført værdi)-data
| Pris til omsætning | - |
| Pris til egenkapital | 5.96 |
| EV i forhold til salg | - |
ØKONOMI
Pr. aktie
Loading...
Data pr. aktie
| Aktuelt antal aktier | 43.85M |
| EPS (TTM) | -5.07 |
| FCF pr. aktie (TTM) | -3.02 |
Resultatopgørelse
Loading...
Resultatopgørelse-data
| Omsætning (TTM) | 0.00 |
| Bruttofortjeneste (TTM) | 0.00 |
| Driftsindkomst (TTM) | -179.62M |
| Nettoindkomst (TTM) | -222.32M |
| EPS (TTM) | -5.07 |
| EPS (1 år frem) | -2.36 |
Marginer
Loading...
Marginer-data
| Bruttomargin (TTM) | - |
| Driftsmargin (TTM) | - |
| Fortjenstmargin (TTM) | - |
Balance
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Balancedata
| Kontanter | 56.76M |
| Nettotilgodehavender | 0.00 |
| Omsætningsaktiver i alt | 290.31M |
| Goodwill | 0.00 |
| Immaterielle aktiver | 0.00 |
| Ejendomme, anlæg og udstyr | 0.00 |
| Sum aktiver | 337.33M |
| Kreditor | 2.96M |
| Kortfristet/nuværende langsigtet gæld | 86.87M |
| Summen af kortfristede forpligtelser | 44.78M |
| Sum gæld | 101.04M |
| Aktionærernes egenkapital | 236.28M |
| Materielle nettoaktiver | 236.28M |
Likviditet
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Kontantstrøm-data
| Likviditet fra driften (TTM) | -125.92M |
| Investeringsudgifter (TTM) | 6.22M |
| Fri pengestrøm (TTM) | -132.14M |
| Udbetalt udbytte (TTM) | 0.00 |
Finansiel indkomst
Loading...
Opret en gratis konto eller log ind for at få adgang til dette diagram
Data om finansiel indkomst
| Egenkapitalafkast | -94.09% |
| Afkast af aktiver | -65.91% |
| Afkast af investeret kapital | -83.30% |
| Kontant afkast af investeret kapital | -49.51% |
INFORMATION OM AKTIER
Aktiediagram
Loading...
Aktiekurs-data
| Åbning | 32.67 |
| Daglig høj | 32.67 |
| Daglig lav | 31.04 |
| Daglig volumen | 284K |
| Højeste gennem alle tider | 33.94 |
| 1 års analytiker estimat | 37.33 |
| Beta | - |
| EPS (TTM) | -5.07 |
| Udbytte pr. aktie | - |
| Ex-div dato | - |
| Næste dato for resultatpræsentation | 23 Mar 2023 |
Nedsidepotensial
Loading...
Nedsidepotensial-data
| ACLX | S&P500 | |
| Nuværende prisfald fra top notering | -5.33% | -14.21% |
| Højeste prisfald | -62.33% | -56.47% |
| Højeste efterår dato | 18 May 2022 | 9 Mar 2009 |
| Gennemsnitlig fald fra toppen | -20.06% | -11.49% |
| Gennemsnitlig tid til nyt højdepunkt | 17 days | 13 days |
| Maks. tid til nyt højdepunkt | 126 days | 1805 days |
OPLYSNINGER OM VIRKSOMHEDEN
Markedsværdi
1.41B
Markedsværdi kategori
Small-cap
Beskrivelse
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. The company's lead ddCAR product candidate is CART-ddBCMA, which is in phase 1 clinical trial for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). It is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Personale
78
Hjemmeside
Investor relationer
-
SEC-indsendelser
Adm. direktør
Land
USA
By
Aktietype
-
CCC-status
-
Utbyttefrekvens
-
ARRANGEMENTER OG PRÆSENTATIONER
ArrangementerPræsentationer
Loading...
FORSTÅ FORRETNINGEN
Loading...
NYHEDER OM VIRKSOMHEDEN
Alle nyhederPressemeddelelser
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
2. februar 2023
SANTA MONICA, Calif. & REDWOOD CITY, Calif., January 30, 2023--Kite, a Gilead Company (NASDAQ: GILD), and Arcellx, Inc. (NASDAQ: ACLX), today announced the closing of the companies’ previously announc...
30. januar 2023
Gilead Sciences (GILD) gets EMA validation for its application for breast cancer drug Trodelvy in the European Union.
4. januar 2023
Acquisitions news from HZNP and AMGN form the key highlights from the biotech sector during the past week.
14. december 2022
Gilead (GILD) announces deals with Arcellx, Inc. and ImmunoGen to strengthen its oncology pipeline.
12. december 2022
Recent initial public offering Arcellx forged a $325 million cancer deal with Gilead Sciences on Friday, and the IPO stock broke out.
9. december 2022
The deal involves an upfront cash payment of $225 million to Arcellx and a $100 million equity investment from Gilead's Kite Pharma.
9. december 2022
Kite, a Gilead Sciences Inc company (NASDAQ: GILD), announced a global strategic collaboration to co-develop and co-commercialize Arcellx Inc's (NASDAQ: ACLX) lead late-stage product candidate, CART-d...
9. december 2022
Gilead Sciences Inc. said Friday that it will co-develop and co-commercialize Arcellx Inc.'s multiple myeloma treatment candidate, which is currently in Phase 2 clinical trials. Gilead will pay Arcell...
9. december 2022
Arcellx, Inc. (NASDAQ: ACLX), a biotechnology company reimagining cell therapy through the development of innovative immunotherapies for patients with cancer and other incurable diseases, today announ...
9. december 2022
Næste side